In Reply to ‘Idarucizumab Dosing in Kidney Failure’

We thank Drs Yip and Deng for their insights on our case report.1 We agree that frequent clinical and laboratory assessment in a patient with life-threatening hemorrhage is essential. Clinical examination of this critically ill patient was constant, and coagulation parameters were measured 10 times during his 3-day hospital course (approximately every 4 hours). We also agree that repeat dosing of idarucizumab may have been beneficial had it been possible, as in the report we cited of dabigatran toxicity in acute kidney injury (AKI).

http://ift.tt/2ynNkN8